Drugs / Conatumumab
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01940172 | Nov 2013 → Sep 2015 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | TetraLogic Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00791011 | Feb 2008 → Jul 2010 | Hodgkins lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma | Amgen | Completed | No outcome recorded |
| Phase 1/27 trials · 1 missed | ||||||
| Phase 1/2 | NCT00819169 | Jan 2009 → Aug 2011 | colorectal cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm, non-small cell lung carcinoma +2 | NantCell, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00630786 | Jan 2008 → May 2009 | colon carcinoma, rectal cancer | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00534027 | Jan 2008 → Mar 2011 | non-small cell lung carcinoma | Amgen | Completed | Missed primary |
| Phase 1/2 | NCT00626704 | Nov 2007 → Aug 2009 | soft tissue sarcoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00625651 | Oct 2007 → Aug 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00630552 | Jun 2007 → Jan 2010 | pancreatic adenocarcinoma | NantCell, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01017822 | — | malignant pancreatic neoplasm | Radiation Therapy Oncology Group | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01327612 | Mar 2011 → Feb 2020 | carcinoid tumor, colorectal cancer, lymphoma, metastatic malignant neoplasm +2 | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00813605 | Mar 2009 → Jan 2011 | colorectal cancer | NantCell, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conatumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630786 ↗ |
| Known as | AMG 655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813605 ↗ |
| Known as | TRAIL-R2 MAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743003 ↗ |
| Known as | TRAIL-R2MAB XG1-048 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743003 ↗ |
| Known as | XG1-048 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743003 ↗ |
| Action | Activate | “fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5)” NCT00625651 ↗1“Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743003 ↗ |
| Modality | Monoclonal antibody | “AMG 655 is a monoclonal antibody directed against TR-2.” NCT00534027 ↗ |
| Route | Intravenous | “AMG 655 at the maximum tolerated dose (Arm 1), AMG 655 at a lower dose (Arm 2), or AMG 655 placebo (Arm 3) IV Q3W.” NCT00534027 ↗ |
| Target | TNFRSF10B | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743003 ↗ |